Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
NextCure announces publication of NC410 preclinical data » 16:08
06/21/21
06/21
16:08
06/21/21
16:08
NXTC

NextCure

$7.87 /

+0.02 (+0.25%)

NextCure announced the…

NextCure announced the publication of preclinical data in the online journal eLife establishing NC410 as a novel immunomedicine targeting immune-excluded regions of collagen-rich tumors and enabling normalization of the tumor immune microenvironment. NC410, currently being evaluated in a Phase 1/2 clinical trial in patients with advanced or metastatic solid tumors, is a first-in-class immunomedicine designed to block immune suppression mediated by LAIR-1, an immunomodulatory receptor expressed on T cells and myeloid cells, including dendritic cells. NC410 is a dimeric LAIR-2 Fc fusion protein that is designed to act as a LAIR-1 decoy by binding with higher affinity to tumoral collagens than human LAIR-1, preventing LAIR-1-mediated immune suppression. This publication demonstrated that NC410 binding was most notable in collagen-rich tumors, such as gastric, ovarian, lung and head and neck, and in regions where immune cells were being excluded. As a result of T cell activation and effector function, NC410 induces specific collagen degradation products that may relate to the enhanced infiltration of immune cells in the tumor and have the potential to be used as clinical biomarkers.

ShowHide Related Items >><<
NXTC NextCure
$7.87 /

+0.02 (+0.25%)

NXTC NextCure
$7.87 /

+0.02 (+0.25%)

03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/04/21 Piper Sandler
NextCure price target lowered to $26 from $32 at Piper Sandler
01/15/21 BofA
NextCure downgraded to Underperform on low conviction in NC318 at BofA
NXTC NextCure
$7.87 /

+0.02 (+0.25%)

Over a month ago
Hot Stocks
NextCure to present NC410 study data at ASCO » 18:44
05/19/21
05/19
18:44
05/19/21
18:44
NXTC

NextCure

$8.16 /

-0.14 (-1.69%)

NextCure announced that…

NextCure announced that clinical trial investigator, Martin Gutierrez, M.D., Director, Phase 1 Program and Co-Chair of Thoracic Oncology at Hackensack University Medical Center, will present a Trials in Progress poster for NC410 at the 2021 American Society of Clinical Oncology Annual Meeting. "We are excited to discuss our rationale for developing NC410 as a first-in-class cancer therapeutic targeting the LAIR pathway as well as our Phase 1/2 clinical trial strategy with the clinical oncology community at ASCO," said Han Myint, M.D., NextCure's chief medical officer. "NC410 demonstrates anti-tumor activity in preclinical models, and we believe it has significant potential across multiple tumor types, including gastric, ovarian, lung head and neck. We look forward to continuing to evaluate NC410 in first-in-human trials and reporting initial clinical data in the second half of 2021."

ShowHide Related Items >><<
NXTC NextCure
$8.16 /

-0.14 (-1.69%)

NXTC NextCure
$8.16 /

-0.14 (-1.69%)

03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/04/21 Piper Sandler
NextCure price target lowered to $26 from $32 at Piper Sandler
01/15/21 BofA
NextCure downgraded to Underperform on low conviction in NC318 at BofA
NXTC NextCure
$8.16 /

-0.14 (-1.69%)

Conference/Events
NextCure management to meet virtually with Roth Capital » 05:55
05/18/21
05/18
05:55
05/18/21
05:55
NXTC

NextCure

$8.03 /

-0.07 (-0.86%)

Virtual Meetings to be…

Virtual Meetings to be held May 17-18 hosted by Roth Capital.

ShowHide Related Items >><<
NXTC NextCure
$8.03 /

-0.07 (-0.86%)

NXTC NextCure
$8.03 /

-0.07 (-0.86%)

03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/04/21 Piper Sandler
NextCure price target lowered to $26 from $32 at Piper Sandler
01/15/21 BofA
NextCure downgraded to Underperform on low conviction in NC318 at BofA
NXTC NextCure
$8.03 /

-0.07 (-0.86%)

Conference/Events
NextCure management to meet virtually with Roth Capital » 04:55
05/17/21
05/17
04:55
05/17/21
04:55
NXTC

NextCure

$8.11 /

+0.07 (+0.87%)

Virtual Meetings to be…

Virtual Meetings to be held May 17-18 hosted by Roth Capital.

ShowHide Related Items >><<
NXTC NextCure
$8.11 /

+0.07 (+0.87%)

NXTC NextCure
$8.11 /

+0.07 (+0.87%)

03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/04/21 Piper Sandler
NextCure price target lowered to $26 from $32 at Piper Sandler
01/15/21 BofA
NextCure downgraded to Underperform on low conviction in NC318 at BofA
NXTC NextCure
$8.11 /

+0.07 (+0.87%)

Conference/Events
NextCure management to meet virtually with Roth Capital » 10:55
05/14/21
05/14
10:55
05/14/21
10:55
NXTC

NextCure

$8.04 /

+ (+0.00%)

Virtual Meetings to be…

Virtual Meetings to be held May 17-18 hosted by Roth Capital.

ShowHide Related Items >><<
NXTC NextCure
$8.04 /

+ (+0.00%)

NXTC NextCure
$8.04 /

+ (+0.00%)

03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/04/21 Piper Sandler
NextCure price target lowered to $26 from $32 at Piper Sandler
01/15/21 BofA
NextCure downgraded to Underperform on low conviction in NC318 at BofA
NXTC NextCure
$8.04 /

+ (+0.00%)

Earnings
NextCure reports Q1 EPS (60c), consensus (59c) » 17:31
05/06/21
05/06
17:31
05/06/21
17:31
NXTC

NextCure

$7.83 /

+0.15 (+1.95%)

Cash, cash equivalents,…

Cash, cash equivalents, and marketable securities, excluding restricted cash as of March 31 were $268.2M as compared with $283.4M as of December 31, 2020. The decrease of $15.2M reflects cash used to fund operations of $13.9M and cash used to purchase fixed assets of $0.8M. Based on its current research and development plans, NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditure requirements into the second half of 2023.

ShowHide Related Items >><<
NXTC NextCure
$7.83 /

+0.15 (+1.95%)

NXTC NextCure
$7.83 /

+0.15 (+1.95%)

03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/04/21 Piper Sandler
NextCure price target lowered to $26 from $32 at Piper Sandler
01/15/21 BofA
NextCure downgraded to Underperform on low conviction in NC318 at BofA
NXTC NextCure
$7.83 /

+0.15 (+1.95%)

Hot Stocks
NextCure presents preclinical data for NC762 at AACR Annual Meeting » 15:49
04/11/21
04/11
15:49
04/11/21
15:49
NXTC

NextCure

$9.62 /

-0.09 (-0.93%)

NextCure presented…

NextCure presented preclinical and investigational new drug-enabling data for NC762 at the American Association for Cancer Research Annual Meeting 2021. NC762 is a humanized monoclonal antibody specific for B7-H4 and is being developed for the treatment of cancer. Key highlights from the presentation include: NC762 demonstrated specificity for human B7-H4, which is widely expressed in multiple cancers; In a dose-dependent manner, NC762 inhibited tumor growth in a xenograft murine tumor model in the absence of peripheral blood mononuclear cells; The inhibitory effect of NC762 on tumor growth was not dependent on T cells or NK cells; however, NK cells contributed to enhanced anti-tumor activity mediated by NC762; Binding to Fc gamma receptors was not required for NC762 activity, suggesting a novel antibody-dependent cellular cytotoxicity-independent mechanism for tumor inhibition; IND-enabling studies in non-human primates demonstrated a half-life of approximately 8-10 days and no safety concerns in toxicology studies or cytokine release assays were observed.

ShowHide Related Items >><<
NXTC NextCure
$9.62 /

-0.09 (-0.93%)

NXTC NextCure
$9.62 /

-0.09 (-0.93%)

03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/04/21 Piper Sandler
NextCure price target lowered to $26 from $32 at Piper Sandler
01/15/21 BofA
NextCure downgraded to Underperform on low conviction in NC318 at BofA
NXTC NextCure
$9.62 /

-0.09 (-0.93%)

Over a quarter ago
Conference/Events
NextCure management to meet virtually with Piper Sandler » 08:08
03/24/21
03/24
08:08
03/24/21
08:08
NXTC

NextCure

$11.52 /

-0.55 (-4.56%)

Virtual Meeting to be…

Virtual Meeting to be held on March 24 hosted by Piper Sandler.

ShowHide Related Items >><<
NXTC NextCure
$11.52 /

-0.55 (-4.56%)

NXTC NextCure
$11.52 /

-0.55 (-4.56%)

03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/04/21 Piper Sandler
NextCure price target lowered to $26 from $32 at Piper Sandler
01/15/21 BofA
NextCure downgraded to Underperform on low conviction in NC318 at BofA
NXTC NextCure
$11.52 /

-0.55 (-4.56%)

Upgrade
NextCure upgraded to Buy from Hold at Truist » 07:14
03/05/21
03/05
07:14
03/05/21
07:14
NXTC

NextCure

$11.38 /

-0.22 (-1.90%)

Truist analyst Asthika…

Truist analyst Asthika Goonewardene upgraded NextCure to Buy from Hold with a price target of $19, up from $13. Updates from the company's R&D day were "very constructive" and offered enough to be positive on NC318, the analyst tells investors in a research note. Goonewardene adds that he expects NC318 to be active in a subset of patients across 3 tumor types, the key one being NSCLC, even though the addressable market for the drug may be smaller than expected. The analyst further states that he sees paths to pivotal trials re-emerging in the next 9-15 months.

ShowHide Related Items >><<
NXTC NextCure
$11.38 /

-0.22 (-1.90%)

NXTC NextCure
$11.38 /

-0.22 (-1.90%)

03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/04/21 Piper Sandler
NextCure price target lowered to $26 from $32 at Piper Sandler
01/15/21 BofA
NextCure downgraded to Underperform on low conviction in NC318 at BofA
01/15/21 BofA
NextCure downgraded to Underperform from Neutral at BofA
NXTC NextCure
$11.38 /

-0.22 (-1.90%)

Upgrade
NextCure upgraded to Buy from Hold at Truist » 06:52
03/05/21
03/05
06:52
03/05/21
06:52
NXTC

NextCure

$11.38 /

-0.22 (-1.90%)

Truist analyst Asthika…

Truist analyst Asthika Goonewardene upgraded NextCure to Buy from Hold with a $19 price target.

ShowHide Related Items >><<
NXTC NextCure
$11.38 /

-0.22 (-1.90%)

NXTC NextCure
$11.38 /

-0.22 (-1.90%)

03/04/21 Piper Sandler
NextCure price target lowered to $26 from $32 at Piper Sandler
01/15/21 BofA
NextCure downgraded to Underperform on low conviction in NC318 at BofA
01/15/21 BofA
NextCure downgraded to Underperform from Neutral at BofA
01/05/21 Benchmark
GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021
NXTC NextCure
$11.38 /

-0.22 (-1.90%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.